Drew Dennison
Angel Investor
St Louis, United States
Drew Dennison is a Series A investor in St Louis focused on Biotechnology and Health Care. Drew Dennison
- Total investments:
- 8
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Drew Dennison invests in
Stages Drew Dennison invests in
Countries Drew Dennison invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Series A
- $6.9M–$43M
Investment Focus
Industry
- Biotechnology 4 (50%)
- Health Care 2 (25%)
- Health Diagnostics 2 (25%)
- Genetics 1 (13%)
- Security 1 (13%)
Stage
- Series A 3 (38%)
- Seed 1 (13%)
- Pre-Seed 1 (13%)
- Series B 1 (13%)
- Series C 1 (13%)
Country
- United States 4 (50%)
- Denmark 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
AI Proteins
|
AI Proteins is a biotechnology company that focuses on the design and engineering of synthetic mini protein therapeutics. The company was founded in 2021 and is headquartered in Andover, Massachusetts. | $42.5M / Series A / Nov 19, 2025 | |
Geneoscopy
|
Geneoscopy is a non-invasive colorectal cancer diagnostic powered by advanced research in computational biology. The company is determined to replace every patient’s least favorite screen: the colonoscopy. Currently there is no test with high enough specificity and sensitivity to allow patients an alternative to the unpleasant, invasivecolonoscopy. Geneoscopy is changing that.It has developed a novel methodology to reliably and consistently extract human RNA transcripts from stool samples and detect changes in gene expression. This provides Geneoscopy a platform to harness the power of RNA to detect, prevent, and guide treatment for gastrointestinal disease. Geneoscopy is currently developing a diagnostic test for the prevention of colorectal cancer and is conducting research on other applications of its technology for tangential indications. | $105M / Series C / Jan 08, 2025 | |
Coana (acquired by Socket)
|
Coana helps software teams tackle the flood of alerts from traditional SCA tools. By using advanced reachability analysis, Coana cuts false alerts by over 80%, freeing up significant engineering time without sacrificing security. Coana is developed by leading program analysis researchers and is backed by Sequoia Capital and Essence VC. | $1.6M / Pre-Seed / Jan 23, 2024 | |
|
AI Proteins
|
AI Proteins is a biotechnology company that focuses on the design and engineering of synthetic mini protein therapeutics. The company was founded in 2021 and is headquartered in Andover, Massachusetts. | $18.2M / Seed / Jan 21, 2022 | |
|
Geneoscopy
|
Geneoscopy is a non-invasive colorectal cancer diagnostic powered by advanced research in computational biology. The company is determined to replace every patient’s least favorite screen: the colonoscopy. Currently there is no test with high enough specificity and sensitivity to allow patients an alternative to the unpleasant, invasivecolonoscopy. Geneoscopy is changing that.It has developed a novel methodology to reliably and consistently extract human RNA transcripts from stool samples and detect changes in gene expression. This provides Geneoscopy a platform to harness the power of RNA to detect, prevent, and guide treatment for gastrointestinal disease. Geneoscopy is currently developing a diagnostic test for the prevention of colorectal cancer and is conducting research on other applications of its technology for tangential indications. | $105M / Series B / Nov 16, 2021 | |
Mana Therapeutics
|
Educating Immune Cells, Eliminating Cancer. Our team of scientists, physicians, and advocates are passionate about one thing: harnessing our immune cells to combat cancer - conferring lifelong immunity to the disease. Meet the team charged with immune cell education and cancer elimination. | $35M / Series A / Jan 08, 2021 | |
Adarza BioSystems
|
Adarza BioSystems is an early-stage medical diagnostics company developing a rapid and label-free biological assay platform for measuring clinical and point-of-care (POC) samples. In addition to performing sophisticated clinical tests within minutes, this technology potentially allowing hundreds of tests to be run simultaneously on a single chip.It was founded in 2008 and headquartered in St Louis, Missouri. | $25M / Series D / Feb 04, 2020 | |
|
Geneoscopy
|
Geneoscopy is a non-invasive colorectal cancer diagnostic powered by advanced research in computational biology. The company is determined to replace every patient’s least favorite screen: the colonoscopy. Currently there is no test with high enough specificity and sensitivity to allow patients an alternative to the unpleasant, invasivecolonoscopy. Geneoscopy is changing that.It has developed a novel methodology to reliably and consistently extract human RNA transcripts from stool samples and detect changes in gene expression. This provides Geneoscopy a platform to harness the power of RNA to detect, prevent, and guide treatment for gastrointestinal disease. Geneoscopy is currently developing a diagnostic test for the prevention of colorectal cancer and is conducting research on other applications of its technology for tangential indications. | $6.9M / Series A / Oct 02, 2019 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Drew Dennison invest in?
Drew Dennison invests primarily in Biotechnology, Health Care and Health Diagnostics startups, most often at Series A and Seed stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Drew Dennison's check size?
Drew Dennison typically joins rounds of $6.9M–$43M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Drew Dennison participates in.
How do I contact Drew Dennison?
Public channels for Drew Dennison include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Drew Dennison last invest?
The most recent investment recorded for Drew Dennison closed in Nov 2025. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
